Drug:
Reaction: DISEASE PROGRESSION
20250101 - 20251231
No. 701 - 800
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 701 | 25012257 |
ES |
52 | 2 |
Disease progression, Skin ulcer, Post procedural fistula, Alopecia, Diarrhoea, Nausea, Pyrexia, Asthenia, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 702 | 25012482 |
BR |
60 | 2 |
Disease progression, Ascites, Interstitial lung disease, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 703 | 25012640 |
CN |
60 | 2 |
Disease progression, |
||||
BEVACIZUMAB, CISPLATIN, PEMETREXED, PEMETREXED DISODIUM, CARBOPLATIN, PREDNISONE, LORLATINIB, |
||||
| 704 | 25012671 |
CA |
86 | 1 |
Disease progression, Neovascular age-related macular degeneration, |
||||
RANIBIZUMAB, |
||||
| 705 | 25012853 |
IN |
57 | 1 |
Drug ineffective, Disease progression, |
||||
LENALIDOMIDE, ELTROMBOPAG, |
||||
| 706 | 25013080 |
IN |
28 | 1 |
Drug ineffective, Disease progression, Off label use, |
||||
ETOPOSIDE, CARBOPLATIN, BENDAMUSTINE HCL, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, IFOSFAMIDE, |
||||
| 707 | 25013424 |
|||
Disease progression, |
||||
CAPIVASERTIB, FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 708 | 25013543 |
FR |
63 | 2 |
Enterocolitis, Drug ineffective, Disease progression, Mucosal inflammation, |
||||
LENALIDOMIDE, AZACITIDINE, AZACITIDINE FOR, FLUDARABINE PHOSPHATE, ERYTHROPOIETIN, (DAUNORUBICIN AND CYTARABINE) LIPOSOME, (DAUNORUBICIN AND CYTARABINE) LIPOSOME, TREOSULFAN, ACYCLOVIR, POSACONAZOLE, POSACONAZOLE DELAYED-RELEASE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOSPORINE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, BUSULFAN, |
||||
| 709 | 25013578 |
CN |
||
Disease progression, |
||||
DEGARELIX, |
||||
| 710 | 25013579 |
CN |
||
Disease progression, |
||||
DEGARELIX, |
||||
| 711 | 25013882 |
JP |
54 | 1 |
Pulmonary tumour thrombotic microangiopathy, Disease progression, |
||||
AVELUMAB, |
||||
| 712 | 25013983 |
US |
||
Disease progression, |
||||
BEVACIZUMAB-AWWB, |
||||
| 713 | 25014097 |
US |
||
Disease progression, |
||||
BEVACIZUMAB-AWWB, |
||||
| 714 | 25014136 |
AT |
2 | |
Metastases to liver, Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 715 | 25014176 |
AR |
||
Disease progression, |
||||
RITUXIMAB, POLATUZUMAB VEDOTIN, ETOPOSIDE, PREDNISONE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, BENDAMUSTINE HCL, |
||||
| 716 | 25014476 |
GB |
1 | |
Disease progression, |
||||
AXICABTAGENE CILOLEUCEL, |
||||
| 717 | 25014576 |
63 | 2 | |
Breast cancer metastatic, Disease progression, Dyspnoea, |
||||
SEMAGLUTIDE, |
||||
| 718 | 25014630 |
RU |
2 | |
Disease progression, |
||||
| 719 | 25014652 |
RU |
2 | |
Disease progression, |
||||
| 720 | 25014969 |
US |
1 | |
Disease progression, |
||||
| 721 | 25015261 |
US |
1 | |
Hallucination, auditory, Drug ineffective, Disease progression, |
||||
PALIPERIDONE PALMITATE, PALIPERIDONE PALMITATE, PALIPERIDONE PALMITATE, |
||||
| 722 | 25006544 |
CA |
1 | |
Disease progression, Paraganglion neoplasm malignant, |
||||
EVEROLIMUS, EVEROLIMUS TABLETS, DACARBAZINE, DACARBAZINE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 723 | 25006646 |
US |
3 | 1 |
Disease progression, Drug ineffective, |
||||
PHENOBARBITAL, LEVETIRACETAM, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, LEVETIRACETAM IN SODIUM CHLORIDE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, FOSPHENYTOIN, FOSPHENYTOIN SODIUM, MIDAZOLAM, MIDAZOLAM HYDROCHLORIDE, EPINEPHRINE, ADRENALINUM, DOPAMINE HYDROCHLORIDE, DOPAMINE, DOPAMINE HYDROCHLORIDE, DOPAMINE, NITRIC OXIDE, NITRIC OXIDE, NITRIC OXIDE, |
||||
| 724 | 25006655 |
US |
21 | 2 |
Disease progression, Disease recurrence, Drug ineffective, Therapy partial responder, Maternal exposure during pregnancy, |
||||
LEVETIRACETAM, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, LEVETIRACETAM IN SODIUM CHLORIDE, LACOSAMIDE, TOPIRAMATE, TOPIRAMATE SPINKLE, MIDAZOLAM, MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM, MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM, MIDAZOLAM HYDROCHLORIDE, PHENYTOIN, FOSPHENYTOIN, FOSPHENYTOIN SODIUM, PERAMPANEL, CLOBAZAM, PROPOFOL, MAGNESIUM, LEVOCARNITINE, LEVOCARNITINE ORAL, VALPROIC ACID, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, CLONAZEPAM, |
||||
| 725 | 25006793 |
US |
61 | 1 |
Disease progression, Incorrect dosage administered, Inappropriate schedule of product administration, |
||||
RIPRETINIB, |
||||
| 726 | 25006813 |
US |
56 | 2 |
Disease progression, |
||||
RIPRETINIB, |
||||
| 727 | 25006890 |
PK |
54 | 2 |
Disease progression, |
||||
TRASTUZUMAB, |
||||
| 728 | 25006903 |
US |
||
Confusional state, Disease progression, Anxiety, |
||||
EDARAVONE, |
||||
| 729 | 25007409 |
JP |
1 | |
Disease progression, Drug ineffective, |
||||
BEVACIZUMAB, FLUOROURACIL, |
||||
| 730 | 25007544 |
SG |
2 | |
Disease progression, |
||||
| 731 | 25007644 |
US |
41 | 2 |
Metastatic gastric cancer, Disease progression, |
||||
BEVACIZUMAB, CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB, |
||||
| 732 | 25007681 |
GB |
||
Disease progression, Drug ineffective, |
||||
DOXORUBICIN, PREDNISONE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYTARABINE, RITUXIMAB, IBRUTINIB, |
||||
| 733 | 25007697 |
GB |
||
Disease progression, Drug ineffective, |
||||
DOXORUBICIN, PREDNISONE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYTARABINE, RITUXIMAB, |
||||
| 734 | 25007711 |
KR |
49 | 2 |
Disease progression, Drug ineffective for unapproved indication, Drug ineffective, |
||||
ETOPOSIDE, DOXORUBICIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CISPLATIN, PACLITAXEL, CARBOPLATIN, |
||||
| 735 | 25007712 |
KR |
55 | 2 |
Disease progression, Drug ineffective for unapproved indication, |
||||
ETOPOSIDE, CISPLATIN, PACLITAXEL, IFOSFAMIDE, |
||||
| 736 | 25007894 |
PK |
60 | 2 |
Disease progression, |
||||
RITUXIMAB, |
||||
| 737 | 25007899 |
US |
||
Disease progression, Laboratory test abnormal, |
||||
CARFILZOMIB, |
||||
| 738 | 25008044 |
PE |
67 | 1 |
Disease progression, Loss of consciousness, Death, |
||||
ATEZOLIZUMAB, |
||||
| 739 | 25008324 |
JP |
1 | |
Disease progression, Drug ineffective, |
||||
BEVACIZUMAB, FLUOROURACIL, |
||||
| 740 | 25008379 |
JP |
||
Disease progression, Drug ineffective, |
||||
BEVACIZUMAB, OXALIPLATIN, FLUOROURACIL, |
||||
| 741 | 25008423 |
JP |
2 | |
Disease progression, Drug ineffective, |
||||
BEVACIZUMAB, FLUOROURACIL, |
||||
| 742 | 25008429 |
CA |
44 | 1 |
Acromegaly, Disease progression, Product prescribing issue, Product dispensing error, Incorrect dose administered, Off label use, |
||||
PEGVISOMANT, PEGVISOMANT, |
||||
| 743 | 25008434 |
KR |
31 | 2 |
Disease progression, Drug ineffective for unapproved indication, Drug ineffective, |
||||
ETOPOSIDE, ETOPOSIDE, DOXORUBICIN, DOXORUBICIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, CISPLATIN, CISPLATIN, CAPECITABINE, CAPECITABINE, |
||||
| 744 | 25008467 |
KR |
51 | 2 |
Disease progression, Drug ineffective for unapproved indication, |
||||
ETOPOSIDE, ETOPOSIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CISPLATIN, CISPLATIN, |
||||
| 745 | 25008603 |
US |
64 | 1 |
Drug ineffective, Non-small cell lung cancer, Peripheral T-cell lymphoma unspecified, Disease progression, Off label use, |
||||
ETOPOSIDE, PREDNISONE, DOXORUBICIN, DOCETAXEL, DOCETAXEL ANHYDROUS, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, RITUXIMAB, PEMBROLIZUMAB, FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE, BRENTUXIMAB VEDOTIN, BRENTUXIMAB VEDOTIN, CISPLATIN, AXICABTAGENE CILOLEUCEL, |
||||
| 746 | 25008618 |
US |
37 | 1 |
Treatment failure, Disease progression, Off label use, |
||||
DOXORUBICIN, DOCETAXEL, DOCETAXEL ANHYDROUS, PACLITAXEL, IFOSFAMIDE, CISPLATIN, |
||||
| 747 | 25008648 |
KR |
64 | 2 |
Disease progression, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, DOCETAXEL, DOCETAXEL ANHYDROUS, ETOPOSIDE, CISPLATIN, |
||||
| 748 | 25008650 |
KR |
31 | 2 |
Disease progression, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, DOCETAXEL, DOCETAXEL ANHYDROUS, ETOPOSIDE, CISPLATIN, CAPECITABINE, |
||||
| 749 | 25008654 |
KR |
49 | 2 |
Disease progression, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOCETAXEL, DOCETAXEL ANHYDROUS, ETOPOSIDE, DOXORUBICIN, CISPLATIN, PACLITAXEL, CARBOPLATIN, |
||||
| 750 | 25008884 |
US |
35 | 1 |
Disease progression, Pulmonary fibrosis, Blood cholesterol increased, Intentional product use issue, |
||||
NINTEDANIB, PREDNISONE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 751 | 25009016 |
DE |
70 | 2 |
Disease progression, Drug ineffective for unapproved indication, |
||||
LENALIDOMIDE, |
||||
| 752 | 25009410 |
JP |
56 | 1 |
Drug ineffective, Renal failure, Disease progression, |
||||
PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, MINOCYCLINE, LEVOFLOXACIN, LEVOFLOXACIN IN 5% DEXTROSE, |
||||
| 753 | 25009472 |
JP |
2 | |
Disease progression, Drug ineffective, |
||||
BEVACIZUMAB, FLUOROURACIL, |
||||
| 754 | 25009482 |
HR |
8 | 2 |
Disease progression, |
||||
METHYLPREDNISOLONE, METHYLPREDNISOLONE, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 755 | 25009494 |
JP |
74 | 2 |
Rash, Metastasis, Disease progression, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, CARBOPLATIN, |
||||
| 756 | 25009498 |
KR |
31 | 2 |
Disease progression, |
||||
CAPECITABINE, |
||||
| 757 | 25009552 |
US |
67 | 1 |
Disease progression, |
||||
TEMOZOLOMIDE, |
||||
| 758 | 25009565 |
US |
37 | 2 |
Disease progression, Drug ineffective, |
||||
AZELAIC ACID, |
||||
| 759 | 25009569 |
CN |
46 | 2 |
Disease progression, |
||||
CAPECITABINE, |
||||
| 760 | 25009573 |
CN |
45 | 1 |
Disease progression, |
||||
OXALIPLATIN, |
||||
| 761 | 25009595 |
US |
4 | 1 |
Disease progression, |
||||
METHOTREXATE, METHOTREXATE SODIUM, INFLIXIMAB, |
||||
| 762 | 25009747 |
HR |
2 | |
COVID-19, Pleural effusion, Disease progression, Metastatic malignant melanoma, Mass, Nodule, |
||||
DABRAFENIB, TRAMETINIB, |
||||
| 763 | 25010054 |
SK |
||
Cardiac failure, Ventricular hypertrophy, Diastolic dysfunction, Disease progression, |
||||
PATISIRAN, PATISIRAN, |
||||
| 764 | 25010367 |
RO |
56 | 1 |
Diarrhoea, Ascites, Disease progression, Weight decreased, Gastrointestinal haemorrhage, Depressive symptom, Mood altered, |
||||
OCTREOTIDE ACETATE, OCTREOTIDE, OCTREOTIDE ACETATE, OCTREOTIDE, OCTREOTIDE ACETATE, OCTREOTIDE, EVEROLIMUS, EVEROLIMUS TABLETS, |
||||
| 765 | 25010680 |
US |
42 | 1 |
Respiratory failure, Disease progression, Metastasis, Therapeutic product effect incomplete, Off label use, |
||||
PRALSETINIB, LORLATINIB, ENTRECTINIB, VINORELBINE, |
||||
| 766 | 25010768 |
AU |
74 | 1 |
Disease progression, Cytokine release syndrome, Electroencephalogram abnormal, |
||||
AXICABTAGENE CILOLEUCEL, |
||||
| 767 | 25011042 |
JP |
1 | |
Disease progression, Drug ineffective, |
||||
BEVACIZUMAB, FLUOROURACIL, |
||||
| 768 | 25001780 |
US |
54 | 1 |
Hospitalisation, Disease progression, Underdose, |
||||
RIPRETINIB, |
||||
| 769 | 25001840 |
ES |
50 | 2 |
Disease progression, |
||||
BEVACIZUMAB, |
||||
| 770 | 25001879 |
US |
64 | |
Disease progression, Lymphadenopathy, |
||||
ZANUBRUTINIB, |
||||
| 771 | 25002143 |
PA |
62 | 2 |
Disease progression, |
||||
ETANERCEPT, |
||||
| 772 | 25002144 |
IT |
83 | 1 |
Disease progression, Condition aggravated, |
||||
| 773 | 25002287 |
AL |
59 | 1 |
Disease progression, Adrenal neoplasm, Retroperitoneal lymphadenopathy, Metastasis, |
||||
ATEZOLIZUMAB, ETOPOSIDE, CARBOPLATIN, |
||||
| 774 | 25002307 |
CN |
56 | 2 |
Disease progression, |
||||
POLATUZUMAB VEDOTIN, |
||||
| 775 | 25002397 |
AR |
55 | |
Disease progression, Leukocytosis, Lymphadenopathy, |
||||
ZANUBRUTINIB, |
||||
| 776 | 25002503 |
US |
42 | 1 |
Disease progression, Off label use, Respiratory failure, Metastasis, |
||||
ENTRECTINIB, PRALSETINIB, LORLATINIB, VINORELBINE, |
||||
| 777 | 25002679 |
CA |
1 | |
Disease progression, Neovascular age-related macular degeneration, |
||||
RANIBIZUMAB, |
||||
| 778 | 25002759 |
US |
||
Drug ineffective, Disease progression, |
||||
CAPECITABINE, TEMOZOLOMIDE, |
||||
| 779 | 25002773 |
US |
72 | 2 |
Disease progression, Drug ineffective, |
||||
CAPECITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, |
||||
| 780 | 25002786 |
US |
1 | |
Disease progression, Drug ineffective, |
||||
AZACITIDINE, AZACITIDINE FOR, GILTERITINIB, |
||||
| 781 | 25002822 |
ES |
77 | 2 |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, SACITUZUMAB GOVITECAN, |
||||
| 782 | 25003264 |
PL |
2 | |
Disease progression, |
||||
ADO-TRASTUZUMAB EMTANSINE, |
||||
| 783 | 25003589 |
GB |
60 | 1 |
Dysphagia, Disease progression, Muscular weakness, Drug ineffective for unapproved indication, |
||||
PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, RITUXIMAB, VENETOCLAX, VENETOCLAX, |
||||
| 784 | 25003736 |
US |
||
Disease progression, |
||||
BEVACIZUMAB-AWWB, |
||||
| 785 | 25004571 |
DE |
||
Disease progression, Metastases to lung, Therapy partial responder, Off label use, Intentional product use issue, |
||||
TRASTUZUMAB, DOCETAXEL, DOCETAXEL ANHYDROUS, |
||||
| 786 | 25004684 |
AU |
46 | 1 |
Phospholipase A2 activity increased, Proteinuria, Nephrotic syndrome, Rash, Diarrhoea, Disease progression, B-lymphocyte count decreased, Therapeutic response decreased, |
||||
RITUXIMAB, RITUXIMAB, RITUXIMAB, OBINUTUZUMAB, CYCLOSPORINE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 787 | 25005760 |
US |
81 | 1 |
Cardiac amyloidosis, Disease progression, Weight decreased, |
||||
TAFAMIDIS, |
||||
| 788 | 25005768 |
ES |
2 | |
Drug ineffective, Disease progression, |
||||
IMATINIB, |
||||
| 789 | 25005782 |
AU |
52 | 1 |
Sepsis, Disease progression, Disease recurrence, Fatigue, Neuropathy peripheral, Pain in extremity, Nausea, Diarrhoea, Drug ineffective, |
||||
AMOXICILLIN, SULFAMETHOXAZOLE AND TRIMETHOPRIM, BEVACIZUMAB, BEVACIZUMAB, LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM, CAPECITABINE, FLUOROURACIL, FLUOROURACIL, IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE, OXALIPLATIN, |
||||
| 790 | 25006150 |
US |
2 | |
Disease progression, Drug ineffective, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 791 | 25006179 |
US |
65 | 2 |
Disease progression, |
||||
DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE, |
||||
| 792 | 25006441 |
JP |
||
Disease progression, |
||||
MARIBAVIR, |
||||
| 793 | 25001292 |
BE |
||
Disease progression, |
||||
ATEZOLIZUMAB, |
||||
| 794 | 25001394 |
ZA |
84 | 2 |
Myocardial infarction, Disease progression, |
||||
ADO-TRASTUZUMAB EMTANSINE, TRASTUZUMAB, PERTUZUMAB, |
||||
| 795 | 25001447 |
PK |
51 | 2 |
Disease progression, |
||||
BEVACIZUMAB, BEVACIZUMAB, |
||||
| 796 | 24997615 |
IT |
60 | 1 |
Disease progression, |
||||
CARBOPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, |
||||
| 797 | 24992634 |
KR |
||
Disease progression, |
||||
TISLELIZUMAB-JSGR, |
||||
| 798 | 24992815 |
US |
38 | 2 |
Disease progression, |
||||
ATEZOLIZUMAB, BEVACIZUMAB, LENVATINIB, SOFOSBUVIR, |
||||
| 799 | 24993062 |
CA |
9 | 1 |
Bruxism, Disease progression, Feeding disorder, Scoliosis, Headache, |
||||
SOMATROPIN, SOMATROPIN, SOMATROPIN, SOMATROPIN, SOMATROPIN, IRON, OXYGEN, 0XYGEN, LEVOTHYROXINE SODIUM, |
||||
| 800 | 24993476 |
JP |
||
Disease progression, Stomatitis, |
||||
MOMELOTINIB, HYDROXYUREA, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28